Has Alisha Heaton, OD received payments from drug or device companies?

Yes. Drug and device makers reported $1,224 in general payments to Alisha Heaton, OD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alisha Heaton, OD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alisha Heaton, OD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alisha Heaton, OD

Optometrist · Post Falls, IDNPI 1659605848

Payments from drug & device makers

$1,224in general payments, 2019–2025

Across 37 payments — averaging $33.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$230
AbbVie$204
Alcon$171
Shire North American Group Inc$146
Biotissue Holdings Inc.$142
Johnson & Johnson Surgical Vision, Inc.$77
plus $255 from 7 others

What the payments were for

Food & beverage$1,224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	8	$230
AbbVie(2 entities)	5	$204
Alcon	3	$171
Shire North American Group Inc	4	$146
Biotissue Holdings Inc.	2	$142
Johnson & Johnson Surgical Vision, Inc.	3	$77
Oyster Point Pharma, Inc.	4	$76
Bausch & Lomb Americas Inc.	3	$56
Notal Vision, Inc.	1	$35
Rxsight Inc	1	$26
Thea Pharma Inc.	1	$25
Sun Pharmaceutical Industries Inc.	1	$23
Johnson & Johnson Vision Care, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XIIDRA$241
TOTAL30$134
VUITY$121
Prokera$117
AmnioGraft$117

How this compares

$1,224 in reported general payments places this provider in the 65th percentile of 304 optometrist providers in Idaho.

See all optometrist providers in Idaho →

Medicare billing

Part B allowed, 2024

$143,355

Medicare patients

826

Services billed

1,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XiidraLifitegrast	98	$136,418
RestasisCyclosporine	86	$112,802
Cyclosporine	53	$32,495
TyrvayaVarenicline Tartrate	31	$22,312
CombiganBrimonidine Tartrate/Timolol	12	$5,812
LumiganBimatoprost	14	$4,653
Loteprednol Etabonate	12	$3,504
Brimonidine Tartrate	30	$1,642
Timolol Maleate	37	$1,462
Latanoprost	78	$1,178
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	79	$848
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol	16	$824
Prednisolone Acetate	19	$679
ErythromycinErythromycin Base	49	$445
ValacyclovirValacyclovir Hcl	17	$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra	$56	$136,41898 claims
AbbVieRestasis, Combigan, Lumigan	$204	$123,267112 claims
Oyster Point Pharma, Inc.Tyrvaya	$76	$22,31231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 304 optometrist providers in Idaho.